← All trials
NCT04670081
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2021
- Primary completion
- Mar 1, 2023
- Completion date
- Mar 1, 2024
- First posted
- Dec 17, 2020
- Last posted
- Dec 17, 2020
- Enrollment
- 144
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of HeidelbergLead sponsor
- University of HeidelbergOverall official - principal investigator
- Humboldt UniversityCollaborator
- German Federal Ministry of Education and ResearchCollaborator
- Usona InstituteCollaborator
- MIND Foundation gGmbHCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.